AstraZeneca reports Phase III results for Ultomiris and Sone-Ve
In the ALXN1210-TMA-313 Phase III trial, Ultomiris did not achieve statistical significance for event-free survival.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance